-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NtvXyM9UWO9VSCDGbRhcMBSLyQHH3GK/su4lmJF2XwbA5R5i/nPxcRJBDSQ27TPH 4UPQvtjUhKwo7YA/gERV/A== 0000950135-09-001006.txt : 20090217 0000950135-09-001006.hdr.sgml : 20090216 20090217080024 ACCESSION NUMBER: 0000950135-09-001006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090213 ITEM INFORMATION: Other Events FILED AS OF DATE: 20090217 DATE AS OF CHANGE: 20090217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21696 FILM NUMBER: 09607084 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 b74228ape8vk.htm ARIAD PHARMACEUTICALS e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2009
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  0-21696
(Commission
File Number) 		  22-3106987
(I.R.S. Employer
Identification No.)
     
26 Landsdowne Street, Cambridge, Massachusetts
(Address of principal executive offices) 		  02139
(Zip Code)
Registrant’s telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

ITEM 8.01 Other Events.
ARIAD Pharmaceuticals, Inc. (the “Company”) is filing this Current Report on Form 8-K to report that a shareholder derivative complaint alleging breaches of fiduciary duties was filed in the Delaware Court of Chancery on February 13, 2009, naming each of the Company’s directors (collectively, the “Directors”) as a defendant and the Company as a nominal defendant. The complaint misrepresents factual information taken from the Company’s public filings, and quotes from and repeats many of the same false statements and mischaracterizations of events set forth in the resignation letter from the four resigning directors that the Company filed with the SEC on a Form 8-K on December 5, 2008. As with the allegations in the directors’ resignation letter, the Company and the Directors unequivocally refute the misstatements and mischaracterizations set forth in the complaint. The Company believes that the claims are without merit and that the complaint constitutes a frivolous lawsuit. The Company and the Directors intend to vigorously oppose the lawsuit, beginning with a motion to dismiss to be filed in the near future.

2

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ARIAD Pharmaceuticals, Inc.
 		  
  By:   /s/ Edward M. Fitzgerald    
    Edward M. Fitzgerald   
    Senior Vice President, Chief Financial Officer   
 
Date: February 17, 2009

3

-----END PRIVACY-ENHANCED MESSAGE-----